In August 2019, the National Institute for Health and Care Excellence (NICE) in the UK recommended using dapagliflozin as adjuvant therapy with insulin in adults with T1DM who had a BMI ≥ 27 kg/m2, but the United States Food and Drug Administration refused to approve its use due to concerns about euglycemic DKA [27], a recognized complication of SGLT2 inhibitors [38]. This evidence concerns the gene INS and type 1 diabetes mellitus.